Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes

Published 03/10/2022, 18:53
Updated 03/10/2022, 19:40
© Reuters. Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes

  • Novo Nordisk (CSE:NOVOb) A/S (NYSE: NVO) has completed posting topline results across its six Phase 3a clinical trials in the ONWARDS program of once-weekly insulin icodec in people with diabetes.
  • In ONWARDS 5 study, once-weekly insulin icodec was found to be non-inferior to once-daily basal insulin in reducing HbA1c. With that, the 52-week open-label trial met its primary endpoint at the end of the study.
  • Novo’s icodec led to a reduction of -1.68% points on HbA1c, compared to -1.31% for the once-daily control. The study comprised 1,085 insulin-naive people with type 2 diabetes. Patients on icodec also used an app to guide their dosing.
  • The news adds to ONWARDS trial readouts dating back to April.
  • In July, the company announced headline results from the ONWARDS 3 and ONWARDS 4 Phase 3a trials with once-weekly insulin icodec.
  • Earlier this month, Novo picked up worldwide marketing rights to Zealand Pharma A/S’s (NASDAQ: ZEAL) diabetes treatment Zegalogue and inked a $1.1 billion buyout of Forma Therapeutics Holdings Inc (NASDAQ: FMTX) for its sickle cell drug.
  • Novo Nordisk expects to file for regulatory approval of once-weekly insulin icodec in the U.S., the EU, and China in 1H of 2023.
  • Price Action: NVO shares are up 2.26% at $101.88 on the last check Monday.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.